Estimating the cost of nosocomial candidemia in the United States [1]

Clinical Infectious Diseases

Volumn 32, Issue 7, 2001, Pages

  Miller, Loren G ^a   Hajjeh, Rana A ^b   Edwards, John E ^a  

^a UCLA MEDICAL CENTER   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT;

CANDIDA; CANDIDIASIS; DISEASE CLASSIFICATION; HEALTH CARE COST; HOSPITAL INFECTION; HUMAN; INFECTION RISK; LETTER; MYCOSIS; NONHUMAN; PRIORITY JOURNAL; UNITED STATES;

CANDIDIASIS; FUNGEMIA; HEALTH CARE COSTS; HUMANS; UNITED STATES;

EID: 0035310920     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/319613     Document Type: Letter

References (6)

1. Nosocomial bloodstream infections in United States hospitals: A three-year analysis
2. Hospital-acquired candidemia: The attributable mortality and excess length of stay
3. The impact of candidemia on length of hospital stay, outcome, and overall cost of illness
4. Accuracy of ICD-9-CM codes in detecting community-acquired pneumococcal pneumonia for incidence and vaccine efficacy studies
5. The epidemiology of candidemia in two United States cities: Results of a population-based active surveillance
6. Population-based surveillance for candida bloodstream infections: Trends in incidence of disease and azole resistance